Artax Biopharma
Cambridge, United States · Biotechnology · 13 employees
Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become fi
Funding history
- Funding Round — $19.0M — May 2026
- Funding Round — $11.0M — Jul 2025
- Funding Round — $11.0M — Aug 2024
- Funding Round — $25.8M — May 2022
- Funding Round — $12.7M — Jan 2022
Recent signals
- May 05, 2026: Raised $19.0M
- Jul 29, 2025: Raised $11.0M
- Aug 09, 2024: Raised $11.0M
- Jan 04, 2024: Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year
- May 18, 2022: Raised $25.8M
- Jan 03, 2022: Raised $12.7M
- Feb 26, 2021: Raised $2.2M in Series seed
- May 04, 2020: Raised $2.0M in Series seed
See plans & pricing → Track Artax Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.